Trial Profile
A Single-centre, Open Single-arm Study Where the Safety, Tolerability and Efficacy of Subcutaneously Administered ILB Will be Evaluated in Patients With Amyotrophic Lateral Sclerosis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Dextran sulfate (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- Sponsors TikoMed
- 25 May 2022 According to a TikoMed media release, this study was published in PLOS ONE today.
- 25 May 2022 Results published in TikoMed Media Release.
- 16 Aug 2021 According to a TikoMed media release, data from this study has been published in the Journal of Personalized Medicine.